RxDoctor Payments Data

Maziar Zamani, MD

Internal Medicine · Laguna Hills, CANPI 1518056027

Payments from drug & device makers

$434in general payments, 2019–2025

Across 18 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$145
  • ANI Pharmaceuticals, Inc.$82
  • Boston Scientific$67
  • GSK$47
  • Astellas Pharma US Inc$28
  • Pfizer$23
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$434 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$276,924
Medicare patients
495
Services billed
2,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$116,571
MounjaroTirzepatide92$102,834
EliquisApixaban124$78,313
XareltoRivaroxaban59$63,351
OzempicSemaglutide49$56,078
FarxigaDapagliflozin Propanediol38$43,857
JanuviaSitagliptin Phosphate72$42,383
TrulicityDulaglutide12$25,813
JanumetSitagliptin Phos/Metformin Hcl19$25,143
Breo ElliptaFluticasone/Vilanterol36$18,356
Levothyroxine Sodium1,078$14,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$12,586
MyrbetriqMirabegron16$12,204
Pantoprazole Sodium314$8,771
Rosuvastatin Calcium227$7,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$78,313124 claims
Novo NordiskOzempic$13$56,07849 claims
GSKBreo Ellipta, Trelegy Ellipta$47$30,94260 claims
Astellas Pharma US IncMyrbetriq$28$12,20416 claims
AbbVieSynthroid$145$6,705127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →